Extracorporeal blood oxygenation and ozonation: clinical and biological implications of ozone therapy

Di Paolo N, Gaggiotti E, Galli F. Redox Report, 2005.

View the abstract on PubMed

Study type
Review
People studied
No participants of its own (review)
Published
2005, Redox Report
Identifiers
PMID 16156950, DOI 10.1179/135100005X38888
Group
Studies of EBO2 / EBOO given to people

What the authors reported

Describes EBOO as run on a high-efficiency apparatus that treats up to 4,800 ml of heparinized blood in 1 h with an oxygen-ozone mixture (0.5-1 microg/ml oxygen), against 250 ml by autohemotherapy, in a standard cycle of 14 one-hour sessions over 7 weeks. The authors report more than 1,200 treatments in 82 patients and state their experience confirms therapeutic potential.

What limits this result

Narrative review from the Siena nephrology and dialysis department, the group behind the EBOO papers in this library. The abstract reports no controlled outcome data, and the clinical statements are the authors' own. Read from the abstract only.

Reports of the procedure as given to patients, and a review of them by its developers. Laboratory and device-development work on the circuit is under background science. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.

How the study was done

Design
Review
Setting
Nephrology and Dialysis Department, University Hospital of Siena, Italy
Read from
Read from the abstract only; where this page says nothing about an item, the abstract does not report it. Read on September 28, 2026.

Source: Abstract on PubMed

Procedure as reported

Ozone concentration
0.5-1 microg/ml oxygen, in an oxygen-ozone mixturemakes it possible to treat with a mixture of oxygen-ozone (0.5-1 microg/ml oxygen) in 1 h of extracorporeal circulation up to 4800 ml of heparinized blood
Blood volume
Up to 4800 ml of heparinized blood in 1 h of extracorporeal circulation
Session length
1 h per sessionThe standard therapeutic cycle lasts for 7 weeks in which 14 treatment sessions of 1 h are performed.
Sessions
14 sessions over 7 weeks (the standard therapeutic cycle)
Anticoagulant
Heparin (the blood is described as heparinized)

In the paper's own units, not converted.

Source: Abstract on PubMed

What it measured

EBOO experience reported in the review
First tested in vitro and then in vivo in sheep and humans: more than 1200 treatments performed in 82 patients
Blood markers after a session of EBOO
4-5-fold increased levels of thiobarbituric acid reactants and a proportional decrease in plasma protein thiols, without any appreciable erythrocyte haemolysis
Clinical experience with EBOO (authors' statement)
The authors state the clinical experience so far confirms the great therapeutic potential of EBOO in severe peripheral arterial disease, coronary disease, cholesterol embolism, severe dyslipidemia, Madelung disease, and sudden deafness of vascular origin

Source: Abstract on PubMed

Safety as reported

Treatment of up to 4800 ml of heparinized blood is described as done without technical or clinical problems

Source: Abstract on PubMed

Where we cite this study

All studies we track ยท How the studies compare